IBOV 171,324.31 ▼ 0.43% IPC MEX 71,674.32 ▼ 0.46% MERVAL 2,848,945 — — USD/BRL5.65▲ 1.12% USD/MXN18.59▼ 0.07% USD/CLP994.00▲ 1.14% USD/COP3,302▼ 0.16% USD/PEN3.41▼ 0.06% USD/ARS1,545▲ 0.03% USD/UYU40.52▲ 3.32% USD/PYG6,185▲ 3.33% USD/BOB11.60▲ 0.86% USD/DOP60.47▲ 0.03% USD/CRC445.25▲ 1.62% USD/GTQ7.65▲ 3.31% USD/HNL26.90▲ 3.30% USD/NIO36.62▲ 2.73% USD/VES902.19▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.09▲ 2.15% USD/TTD6.71▲ 2.19% EUR/BRL6.25▲ 0.26% BRENT 95.85 ▲ 3.33% WTI 88.77 ▲ 2.59% IRON ORE 161.91 — — COPPER 6.21 ▼ 1.09% GOLD 3,886 ▼ 2.87% SILVER 50.06 ▼ 3.51% SOY 1,220 ▼ 0.77% CORN 442.25 ▼ 1.28% WHEAT 582.50 ▼ 2.84% COFFEE 275.10 ▲ 2.27% SUGAR 18.22 ▼ 1.41% ORANGE JUICE 140.60 ▼ 3.53% COTTON 78.56 ▲ 0.05% COCOA 5,187 ▲ 5.71% BEEF 223.05 ▲ 1.86% CATTLE 331.80 ▼ 0.25% LITHIUM 59.43 ▼ 2.69% PETR4 44.70 ▲ 2.64% VALE3 63.95 ▼ 0.75% ITUB4 41.68 ▼ 0.10% BBDC4 14.32 ▼ 0.07% ABEV3 15.75 ▼ 0.63% BBAS3 15.48 ▼ 8.35% B3SA3 14.76 ▼ 0.27% WEGE3 51.65 ▲ 0.08% PRIO3 63.30 ▲ 2.98% SUZB3 56.04 ▲ 4.16% RENT3 29.58 ▼ 2.18% AZZA3 16.90 ▲ 9.95% CSAN3 2.85 ▼ 5.94% RAIZ4 0.30 ▼ 98.60% PCAR3 2.39 ▼ 5.91% GMAT3 3.84 ▼ 5.88% PSSA3 45.94 ▼ 0.09% CVCB3 0.84 ▼ 2.33% POSI3 3.37 ▲ 1.51% SLCE3 18.36 ▲ 7.68% NATU3 5.33 ▼ 5.16% BRKM5 3.07 ▲ 5.14% RANI3 8.18 ▼ 2.50% CSNA3 4.23 ▼ 6.42% IBOV 171,324.31 ▼ 0.43% IPC MEX 71,674.32 ▼ 0.46% MERVAL 2,848,945 — — USD/BRL 5.65 ▲ 1.12% USD/MXN 18.58 ▼ 0.10% USD/CLP 994.00 ▲ 1.14% USD/COP 3,303 ▼ 0.13% USD/PEN 3.41 ▼ 0.03% USD/ARS 1,545 ▲ 0.03% USD/UYU 40.52 ▲ 3.32% USD/PYG 6,185 ▲ 3.33% USD/BOB 11.60 ▲ 0.86% USD/DOP 60.47 ▲ 0.03% USD/CRC 445.25 ▲ 1.62% USD/GTQ 7.65 ▲ 3.31% USD/HNL 26.90 ▲ 3.30% USD/NIO 36.62 ▲ 2.73% USD/VES 902.19 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.09 ▲ 2.15% USD/TTD 6.71 ▲ 2.19% EUR/BRL 6.25 ▲ 0.26% BRENT 95.85 ▲ 3.33% WTI 88.77 ▲ 2.59% IRON ORE 161.91 — — COPPER 6.21 ▼ 1.09% GOLD 3,886 ▼ 2.87% SILVER 50.06 ▼ 3.51% SOY 1,220 ▼ 0.77% CORN 442.25 ▼ 1.28% WHEAT 582.50 ▼ 2.84% COFFEE 275.10 ▲ 2.27% SUGAR 18.22 ▼ 1.41% ORANGE JUICE 140.60 ▼ 3.53% COTTON 78.56 ▲ 0.05% COCOA 5,187 ▲ 5.71% BEEF 223.05 ▲ 1.86% CATTLE 331.80 ▼ 0.25% LITHIUM 59.43 ▼ 2.69% PETR4 44.70 ▲ 2.64% VALE3 63.95 ▼ 0.75% ITUB4 41.68 ▼ 0.10% BBDC4 14.32 ▼ 0.07% ABEV3 15.75 ▼ 0.63% BBAS3 15.48 ▼ 8.35% B3SA3 14.76 ▼ 0.27% WEGE3 51.65 ▲ 0.08% PRIO3 63.30 ▲ 2.98% SUZB3 56.04 ▲ 4.16% RENT3 29.58 ▼ 2.18% AZZA3 16.90 ▲ 9.95% CSAN3 2.85 ▼ 5.94% RAIZ4 0.30 ▼ 98.60% PCAR3 2.39 ▼ 5.91% GMAT3 3.84 ▼ 5.88% PSSA3 45.94 ▼ 0.09% CVCB3 0.84 ▼ 2.33% POSI3 3.37 ▲ 1.51% SLCE3 18.36 ▲ 7.68% NATU3 5.33 ▼ 5.16% BRKM5 3.07 ▲ 5.14% RANI3 8.18 ▼ 2.50% CSNA3 4.23 ▼ 6.42%
since 2009
Friday, November 13, 2026

Latest News Brazil

Chinese Pharmaceutical Firm Says Its Vaccine Against Covid-19 Is Safe

By · · 2 min read

RIO DE JANEIRO, BRAZIL – Chinese pharmaceutical company Sinopharm reported its vaccine developed against the novel coronavirus is safe and has proven successful in developing strong antibodies in stages 1 and 2 of trials. All trial subjects were administered two doses of the vaccine every three to four weeks and developed antibodies capable of neutralizing the virus.

The news was released shortly after the world reached the ten million case mark for Covid-19 without any treatment yet approved for regular use, so every treatment is considered experimental.

0
This is the second vaccine developed by the company and the first to show positive results.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Clinical trials for Sinopharm’s vaccine began on April 27th, with 1,120 randomly selected volunteers. It was double-blind research, which implies that neither the researchers nor the patients knew what was being administered against the disease – one of the most assertive ways to prove a study’s efficacy. There was also one group that was administered a placebo version of the vaccine.

The phamaceutical company is expanding its vaccine manufacturing capacity against SARS-CoV-2. According to the company, its plants in Wuhan and Beijing can produce at least 200 million doses of potential protection. This is the second vaccine developed by the company and the first to show positive results.

In all, another 200 vaccines are under development by pharmaceutical companies in cooperation with universities and research centers all over the planet. Only 15 of these have gone into clinical trials and are considered potential candidates to eliminate Covid-19 infection. One such candidate is from Oxford University in partnership with the AstraZeneca pharmaceutical firm, which will be tested in Brazil.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Colombia's president announces a new cartel airstrike”

China is developing vaccines in five categories – inactive, protein-based, attenuated, adenovirus-based, and nucleic acid-based. China’s Coronavac, developed by Sinovac Biotech, will be tested on 9,000 people in Brazil through a partnership with the Butantan Institute. This option was developed based on the virus itself.

Source: Exame

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.